摘要
目的:评价硝苯地平联合厄贝沙坦治疗中国人群2型糖尿病合并高血压患者高血压的效果。方法:检索《万方数据库》、《中国知网》、《维普数据库》、Pubmed、Medline Complete、Elsevier以及Global Health中从建库至2014年10月发表的关于硝苯地平联合厄贝沙坦治疗2型糖尿病合并高血压的随机对照试验研究(RCT),提取相关数据并应用RevMan5.1统计学软件进行Meta分析。结果:共纳入13篇相关文献,共1 562例糖尿病合并高血压患者,其中联合用药试验组801例,单治疗对照组761例。治疗后,试验组的收缩压和舒张压水平、24h尿微量白蛋白均显著低于对照组(均P<0.05);试验组与对照组的血糖水平均明显降低,但两组差异没有统计学意义(P>0.05)。结论:在降压和保护肾功能方面,联合用药(硝苯地平联合厄贝沙坦)优于单用药物。
Objective：To evaluate the clinical effect of combination of nifedipine and irbesartan on hypertension in patients with diabetes and hypertension in the Chinese population. Method： The randomized controlled trials （RCTs） was performed with database search of the Wanfang database, CNKI, VIP database, Pubmed, Medline Complete, Elsevier, Global Health on the combination of nifedipine and irbesartan in treatment of diabetes and hy- pertension, to retrieve documents from the building of database to October 2014, then relevent date were extrac- ted. RevMan5.1 statistical software was used for meta-analysis. Result.. A total of thirteen literatures and 1 562 ca- ses were included in this study, which consisted of 801 cases as the trial group and 761 controls. Meta-analysis showed that blood pressures and 24 hours urinary albumin in trail group were significantly lower than those in con- trol group after treatment （both P〈0.05） ; the blood glucose levels were depressed between the two groups and there was no significant difference between the two groups. Conclusion： Combination therapy is more effective for the blood pressure control and the protection of renal function than the single usage.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2015年第2期167-171,共5页
Journal of Clinical Cardiology
